Pfizer Inc. $PFE Stock Holdings Increased by Manchester Capital Management LLC

Manchester Capital Management LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 50,005 shares of the biopharmaceutical company’s stock after purchasing an additional 2,361 shares during the period. Manchester Capital Management LLC’s holdings in Pfizer were worth $1,212,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Westbourne Investments Inc. bought a new position in shares of Pfizer in the 1st quarter valued at approximately $2,411,000. Bourne Lent Asset Management Inc. raised its position in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after purchasing an additional 18,200 shares during the period. Strs Ohio acquired a new stake in shares of Pfizer in the first quarter worth $49,968,000. IFM Investors Pty Ltd lifted its stake in shares of Pfizer by 3.8% in the second quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock worth $27,322,000 after buying an additional 41,263 shares during the last quarter. Finally, Intrua Financial LLC grew its stake in Pfizer by 17.4% in the 1st quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company’s stock valued at $1,986,000 after buying an additional 11,643 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.26 on Tuesday. The firm has a market capitalization of $143.61 billion, a price-to-earnings ratio of 13.44, a PEG ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The business has a fifty day simple moving average of $24.87 and a 200 day simple moving average of $24.51. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer’s dividend payout ratio is presently 100.00%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PFE. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Morgan Stanley decreased their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Scotiabank started coverage on Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.39.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.